Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
    • Alatise KL, Gardner S, Alexander-Bryant A.
    • Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246.

    • Penetrance of Gastric Adenocarcinoma Susceptibility Genes: A Systematic Review.
    • Hosseini S, Acar A, Sen M, Meeder K, Singh P, Yin K, Sutton JM, Hughes K.
    • Ann Surg Oncol. 2022 Dec 17. doi: 10.1245/s10434-022-12829-x. Epub ahead of print.
    • Review

    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.

    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.

    • Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors.
    • Lieberenz J, Levy M, Alvarado R, Paul S, Cobleigh M, Usha L, Stempel L.
    • J Am Coll Radiol. 2022 Dec 11:S1546-1440(22)00895-X. doi: 10.1016/j.jacr.2022.11.010. Epub ahead of print.

    • Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    • Jiao Y, Truong T, Eon-Marchais S, Mebirouk N, Caputo SM, Dondon MG, Karimi M, Le Gal D, Beauvallet J, Le Floch É, Dandine-Roulland C, Bacq-Daian D, Olaso R, Albuisson J, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaillé M, Chiesa J, Colas C, Collonge-Rame MA, Coupier I, Delnatte C, De Pauw A, Dreyfus H, Fert-Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Golmard L, Lasset C, Lejeune-Dumoulin S, Léoné M, Limacher JM, Lortholary A, Luporsi É, Mari V, Maugard CM, Mortemousque I, Mouret-Fourme E, Nambot S, Noguès C, Popovici C, Prieur F, Pujol P, Sevenet N, Sobol H, Toulas C, Uhrhammer N, Vaur D, Venat L, Boland-Augé A, Guénel P, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
    • Eur J Cancer. 2022 Nov 13 [2023 Jan 1];179:76-86. doi: 10.1016/j.ejca.2022.11.007. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Germline findings in patients with advanced malignancies screened with paired blood–tumour testing for personalised treatment approaches.
    • Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, Liebmann A, Haack TB, Neumann M, Bonzheim I, Forschner A, Kopp HG, Herster F, Hartkopf A, Bitzer M, Malek NP, Brecht IB, Ruhm K, Möller Y, Löwenheim H, Ossowski S, Rieß OH, Schroeder C.
    • Eur J Cancer. 2022 Nov 8 [2023 Jan 1];179:48-55. doi: 10.1016/j.ejca.2022.11.003. Epub ahead of print.

    • Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    • Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A.
    • Histopathology. 2023 Jan;82(1):162-169. doi: 10.1111/his.14794.

    • Lessons learned with a longer follow-up from SOLO 1.
    • Paulino E.
    • J Gynecol Oncol. 2023 Jan;34:e29. doi: 10.3802/jgo.2023.34.e29. Epub 2022 Dec 7.

    • Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
    • Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM.
    • Cancers (Basel). 2022 Dec 16;14(24):6223. doi: 10.3390/cancers14246223.

    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.

    • Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer.
    • Seymour C.
    • OncLive. 2022 Dec 16.

    Related:

    •• Identifier: NCT03705156: Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient. (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
    • Harris J.
    • OncLive. 2022 Dec 15.

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)

    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.

    • Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    • Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P, Marton MJ.
    • BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z.

    • Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
    • Lelong M, Raoul JL, Touchefeu Y, Berthelot JM, Arnolfo P, Matysiak-Budnik T, Senellart H.
    • Clin Case Rep. 2022 Dec 12;10(12):e6718. doi: 10.1002/ccr3.6718.

    • Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
    • Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A.
    • Breast Cancer Res Treat. 2022 Dec 9. doi: 10.1007/s10549-022-06822-x. Epub ahead of print.

    • Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
    • Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Niger M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M.
    • Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02086-w. Epub ahead of print.

    • Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    • Kristeleit RS, Drew Y, Oza AM, Domchek SM, Banerjee S, Glasspool RM, Balmaña J, Chen LM, Patel MR, Burris HA, Safra T, Borrow J, Lin KK, Goble S, Maloney L, Shapira-Frommer R.
    • Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022-y. Epub ahead of print.

    Related:

    •• Identifier: NCT01482715: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Dec 9.)

    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.

    • BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.
    • Choi E, Mun GI, Lee J, Lee H, Cho J, Lee YS.
    • Biomed Pharmacother. 2022 Dec 6;158:114090. doi: 10.1016/j.biopha.2022.114090. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    • Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A.
    • Histopathology. 2023 Jan;82(1):162-169. doi: 10.1111/his.14794.

    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.